Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Change in Acquisitions & Divestments (2016 - 2025)

Integra Lifesciences Holdings' Change in Acquisitions & Divestments history spans 9 years, with the latest figure at $7.0 million for Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments fell 80.14% year-over-year to $7.0 million; the TTM value through Dec 2025 reached $37.3 million, up 23.07%, while the annual FY2025 figure was $7.0 million, 87.16% down from the prior year.
  • Change in Acquisitions & Divestments for Q4 2025 was $7.0 million at Integra Lifesciences Holdings, down from $35.2 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $35.2 million in Q4 2024 and bottomed at -$4.9 million in Q4 2022.
  • The 4-year median for Change in Acquisitions & Divestments is $76000.0 (2021), against an average of $7.5 million.
  • The largest annual shift saw Change in Acquisitions & Divestments tumbled 6359.21% in 2022 before it crashed 80.14% in 2025.
  • A 4-year view of Change in Acquisitions & Divestments shows it stood at -$76000.0 in 2021, then plummeted by 6359.21% to -$4.9 million in 2022, then soared by 818.07% to $35.2 million in 2024, then plummeted by 80.14% to $7.0 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Change in Acquisitions & Divestments are $7.0 million (Q4 2025), $35.2 million (Q4 2024), and -$4.9 million (Q4 2022).